Helixgate

Helixgate

Uncategorized

GSK cuts deal with Sino to broaden reach of hepatitis B drug

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

Read More

Published

on

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

No FDA permission, no problem: New flavored vape policy worries experts

The tobacco industry chalked up another win on Friday with a new policy announced by the Food and Drug Administration that gives what one expert called a “get-out-of-jail-free card” to some manufacturers illegally selling e-cigarettes and nicotine pouches.

The FDA has a significant backlog of applications from the makers of vapes and nicotine pouches seeking authorization to sell their products. Some have gone ahead and put their products on sale anyway while awaiting word from the agency. In the new guidance, first reported by the New York Times, the agency said it will not prioritize cracking down on illegal sales under two conditions.

Read the rest…

Read More

Published

on

The tobacco industry chalked up another win on Friday with a new policy announced by the Food and Drug Administration that gives what one expert called a “get-out-of-jail-free card” to some manufacturers illegally selling e-cigarettes and nicotine pouches.

The FDA has a significant backlog of applications from the makers of vapes and nicotine pouches seeking authorization to sell their products. Some have gone ahead and put their products on sale anyway while awaiting word from the agency. In the new guidance, first reported by the New York Times, the agency said it will not prioritize cracking down on illegal sales under two conditions.

Read the rest…

Read More

Continue Reading

Uncategorized

Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push

Published

on

Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues.

The drugmaker published a new five-year business plan on Monday …

Continue Reading

Uncategorized

New home for Novo’s Parkinson’s cell therapy; GSK turns to China for hep B drug

Published

on

Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial:

🧠 Novo’s Parkinson’s cell therapy finds a biotech home: Novo Nordisk has found a home for an early-stage …

Continue Reading
Advertisement

Trending